...
sclx-img

Scilex Holding Company, Common Stock

SCLX

NAQ

$0.5075

-$0.01

(-1.94%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$79.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.20M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.15
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.46 L
$2.63 H
$0.5075

About Scilex Holding Company, Common Stock

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameSCLXSectorS&P500
1-Week Return-21.56%-2.27%-0.57%
1-Month Return-31.42%-3.96%1.21%
3-Month Return-55.87%-9.7%7.57%
6-Month Return-65.94%-3.37%11.45%
1-Year Return-55.87%3.71%28.48%
3-Year Return-94.95%3.8%29.52%
5-Year Return-94.85%39.78%90.66%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue21.03M23.56M31.32M38.03M46.74M[{"date":"2019-12-31","value":45,"profit":true},{"date":"2020-12-31","value":50.4,"profit":true},{"date":"2021-12-31","value":67,"profit":true},{"date":"2022-12-31","value":81.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue5.80M2.15M3.63M10.80M15.68M[{"date":"2019-12-31","value":37,"profit":true},{"date":"2020-12-31","value":13.7,"profit":true},{"date":"2021-12-31","value":23.17,"profit":true},{"date":"2022-12-31","value":68.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit15.23M21.41M27.68M27.24M31.06M[{"date":"2019-12-31","value":49.03,"profit":true},{"date":"2020-12-31","value":68.93,"profit":true},{"date":"2021-12-31","value":89.12,"profit":true},{"date":"2022-12-31","value":87.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin72.41%90.88%88.40%71.61%66.45%[{"date":"2019-12-31","value":79.68,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.27,"profit":true},{"date":"2022-12-31","value":78.8,"profit":true},{"date":"2023-12-31","value":73.12,"profit":true}]
Operating Expenses153.93M56.67M63.52M77.87M136.49M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":36.82,"profit":true},{"date":"2021-12-31","value":41.27,"profit":true},{"date":"2022-12-31","value":50.59,"profit":true},{"date":"2023-12-31","value":88.67,"profit":true}]
Operating Income(138.69M)(35.26M)(35.84M)(50.63M)(105.43M)[{"date":"2019-12-31","value":-13869500000,"profit":false},{"date":"2020-12-31","value":-3525800000,"profit":false},{"date":"2021-12-31","value":-3583800000,"profit":false},{"date":"2022-12-31","value":-5063400000,"profit":false},{"date":"2023-12-31","value":-10543100000,"profit":false}]
Total Non-Operating Income/Expense(56.33M)(25.43M)(92.34M)17.67M(10.41M)[{"date":"2019-12-31","value":-318.77,"profit":false},{"date":"2020-12-31","value":-143.92,"profit":false},{"date":"2021-12-31","value":-522.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-58.92,"profit":false}]
Pre-Tax Income(178.59M)(47.57M)(88.42M)(23.36M)(114.32M)[{"date":"2019-12-31","value":-17859200000,"profit":false},{"date":"2020-12-31","value":-4757200000,"profit":false},{"date":"2021-12-31","value":-8841900000,"profit":false},{"date":"2022-12-31","value":-2336000000,"profit":false},{"date":"2023-12-31","value":-11431800000,"profit":false}]
Income Taxes2.00K(53.00K)5.00K4.00K13.00K[{"date":"2019-12-31","value":15.38,"profit":true},{"date":"2020-12-31","value":-407.69,"profit":false},{"date":"2021-12-31","value":38.46,"profit":true},{"date":"2022-12-31","value":30.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(178.59M)(47.52M)(88.42M)(23.36M)(114.33M)[{"date":"2019-12-31","value":-17859400000,"profit":false},{"date":"2020-12-31","value":-4751900000,"profit":false},{"date":"2021-12-31","value":-8842400000,"profit":false},{"date":"2022-12-31","value":-2336400000,"profit":false},{"date":"2023-12-31","value":-11433100000,"profit":false}]
Income From Continuous Operations(178.59M)(47.52M)(1.01M)(23.36M)(110.81M)[{"date":"2019-12-31","value":-17859400000,"profit":false},{"date":"2020-12-31","value":-4751900000,"profit":false},{"date":"2021-12-31","value":-100549800,"profit":false},{"date":"2022-12-31","value":-2336400000,"profit":false},{"date":"2023-12-31","value":-11081500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(178.59M)(47.52M)(88.42M)(23.36M)(114.33M)[{"date":"2019-12-31","value":-17859400000,"profit":false},{"date":"2020-12-31","value":-4751900000,"profit":false},{"date":"2021-12-31","value":-8842400000,"profit":false},{"date":"2022-12-31","value":-2336400000,"profit":false},{"date":"2023-12-31","value":-11433100000,"profit":false}]
EPS (Diluted)--0.15(0.07)(1.29)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-47.62,"profit":false},{"date":"2023-12-31","value":-875.37,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SCLX
Cash Ratio 0.03
Current Ratio 0.20
Quick Ratio 0.19

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SCLX
ROA (LTM) -53.64%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SCLX
Debt Ratio Lower is generally better. Negative is bad. 3.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -2.05

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SCLX
Trailing PE NM
Forward PE NM
P/S (TTM) 1.34
P/B 28.85
Price/FCF 31
EV/R 3.31
EV/Ebitda NM

FAQs

What is Scilex Holding Company share price today?

Scilex Holding Company (SCLX) share price today is $0.5075

Can Indians buy Scilex Holding Company shares?

Yes, Indians can buy shares of Scilex Holding Company (SCLX) on Vested. To buy Scilex Holding Company from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SCLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Scilex Holding Company be purchased?

Yes, you can purchase fractional shares of Scilex Holding Company (SCLX) via the Vested app. You can start investing in Scilex Holding Company (SCLX) with a minimum investment of $1.

How to invest in Scilex Holding Company shares from India?

You can invest in shares of Scilex Holding Company (SCLX) via Vested in three simple steps:

  • Click on Sign Up or Invest in SCLX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Scilex Holding Company shares
What is Scilex Holding Company 52-week high and low stock price?

The 52-week high price of Scilex Holding Company (SCLX) is $2.63. The 52-week low price of Scilex Holding Company (SCLX) is $0.46.

What is Scilex Holding Company price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Scilex Holding Company (SCLX) is

What is Scilex Holding Company price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Scilex Holding Company (SCLX) is 28.85

What is Scilex Holding Company dividend yield?

The dividend yield of Scilex Holding Company (SCLX) is 0.00%

What is the Market Cap of Scilex Holding Company?

The market capitalization of Scilex Holding Company (SCLX) is $79.01M

What is Scilex Holding Company’s stock symbol?

The stock symbol (or ticker) of Scilex Holding Company is SCLX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top